Department of Pediatrics, Division of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Hum Brain Mapp. 2022 May;43(7):2328-2347. doi: 10.1002/hbm.25790. Epub 2022 Feb 10.
This study compared acoustic and neural changes accompanying two treatments matched for intensive dosage but having two different treatment targets (voice or articulation) to dissociate the effects of treatment target and intensive dosage in speech therapies. Nineteen participants with Parkinsonian dysphonia (11 F) were randomized to three groups: intensive treatment targeting voice (voice group, n = 6), targeting articulation (articulation group, n = 7), or an untreated group (no treatment, n = 6). The severity of dysphonia was assessed by the smoothed cepstral peak prominence (CPPS) and neuronal changes were evaluated by cerebral blood flow (CBF) recorded at baseline, posttreatment, and 7-month follow-up. Only the voice treatment resulted in significant posttreatment improvement in CPPS, which was maintained at 7 months. Following voice treatment, increased activity in left premotor and bilateral auditory cortices was observed at posttreatment, and in the left motor and auditory cortices at 7-month follow-up. Articulation treatment resulted in increased activity in bilateral premotor and left insular cortices that were sustained at a 7-month follow-up. Activation in the auditory cortices and a significant correlation between the CPPS and CBF in motor and auditory cortices was observed only in the voice group. The intensive dosage resulted in long-lasting behavioral and neural effects as the no-treatment group showed a progressive decrease in activity in areas of the speech motor network out to a 7-month follow-up. These results indicate that dysphonia and the speech motor network can be differentially modified by treatment targets, while intensive dosage contributes to long-lasting effects of speech treatments.
本研究比较了两种强化剂量治疗方法(针对语音或发音)伴随的声学和神经变化,以区分治疗目标和强化剂量对语音治疗的影响。19 名帕金森氏病性发声障碍患者(11 名女性)被随机分为三组:针对语音的强化治疗组(语音组,n=6)、针对发音的强化治疗组(发音组,n=7)或未治疗组(无治疗组,n=6)。通过平滑倒谱峰值突出度(CPPS)评估发声障碍的严重程度,通过在基线、治疗后和 7 个月随访时记录的脑血流(CBF)评估神经元变化。只有语音治疗在 CPPS 方面显示出显著的治疗后改善,并且在 7 个月时得以维持。在语音治疗后,观察到左运动前区和双侧听觉皮质的活动增加,在治疗后和 7 个月随访时观察到左运动和听觉皮质的活动增加。发音治疗导致双侧运动前区和左侧岛叶皮质的活动增加,并在 7 个月随访时持续增加。只有在语音组中观察到听觉皮质的激活和 CPPS 与运动和听觉皮质的 CBF 之间的显著相关性。强化剂量导致长期的行为和神经效应,因为无治疗组在 7 个月随访时显示出言语运动网络中区域的活动逐渐减少。这些结果表明,治疗目标可以对发声障碍和言语运动网络进行不同的修饰,而强化剂量有助于语音治疗的长期效果。